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Drug-induced mitochondrial dysfunction has been hypothesized to be an important determining factor in
the onset of drug-induced liver injury. It is essential to develop robust screens with which to identify
drug-induced mitochondrial toxicity and to dissect its role in hepatotoxicity. In this study we have
characterised a mechanistically reﬁned HepG2 model, using a panel of selected hepatotoxicants and
non-hepatotoxicants. We have demonstrated that acute metabolic modiﬁcation, via glucose-deprivation
over a 4 h period immediately prior to compound addition, is sufﬁcient to allow the identiﬁcation of
drugs which induce mitochondrial dysfunction, in the absence of cell death over a short exposure (2–
8 h) using a plate-based screen to measure cellular ATP content and cytotoxicity. These effects were
veriﬁed by measuring changes in cellular respiration, via oxygen consumption and extracellular acidiﬁca-
tion rates. Overall, these studies demonstrate the utility of HepG2 cells for the identiﬁcation of mitochon-
drial toxins which act directly on the electron transport chain and that the dual assessment of ATP
content alongside cytotoxicity provides an enhanced mechanistic understanding of the causes of toxicity.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-induced liver injury (DILI) is a major clinical problem.
Hepatic adverse drug reactions have a global incidence of 13.9
per 100,000 inhabitants/year and over 1000 drugs are known to
induce DILI. However, in many cases DILI is not predictable from
the primary pharmacology of the drug, is not detected pre-
clinically, and in most cases have no deﬁned mechanisms
(Hussaini and Farrington, 2014). Drug-induced mitochondrial
dysfunction has been hypothesized to be a determining link in
the onset of such idiosyncratic DILI and 50% of drugs with Black
Box Warnings for DILI contain mitochondrial liabilities (Boelsterli
and Lim, 2007; Labbe et al., 2008). Due to several high proﬁle drugwithdrawals and clinical trial failures, such as ﬁaluridine and tro-
glitazone, in which mitochondrial toxicity has been implicated it
is essential to develop robust screens with which to identify the
potential for mitochondrial toxicity in new chemical entities and
models which can be used to link the onset of mitochondrial dys-
function with cell death and ultimately the hepatotoxic response.
Mitochondrial toxicity is difﬁcult to model in vivo as typical in-
bred rodent models are young and healthy with a large respiratory
capacity (Pereira et al., 2012). Hence, their efﬁciently functioning
mitochondria can tolerate damage and toxicity is not induced.
Some progress has been made in producing transgenic mice, such
as SOD2(+/-), in which underlying mitochondrial stress is hypothe-
sised to enhance sensitivity to mito-hepatotoxins (Ong et al., 2007;
Ramachandran et al., 2011). Deﬁciencies also exist in the models of
mitochondrial toxicity in vitro. In most standard preclinical models
the tumour-derived cells, such as HepG2 cells, have gained the
ability to vary routes of energy production allowing them to utilise
glycolysis alongside oxidative phosphorylation (OXPHOS) in order
to sustain continued growth in anaerobic conditions. However, this
reduces their sensitivity to mitotoxicants. This area was trans-
formed by the description of a technique to confer mitochondrial
susceptibility to HepG2 cells by culturing the cells in media in
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blocking ATP generation via glycolysis and forcing the cells to rely
upon OXPHOS for the production of ATP (Marroquin et al., 2007).
Subsequently this model has been adopted by many pharmaceuti-
cal companies in order to screen for mitochondrial toxicity
preclinically and several publications have detailed its relevance
for the investigation of mitochondrial toxicity in several cell types
(Pereira et al., 2012; Swiss et al., 2013; Will and Dykens, 2014).
Indeed, a survey commissioned by the MIP-DILI (Mechanism-based
Integrated systems for the Prediction of Drug-Induced Liver Injury)
consortia revealed that 75% of the eight pharmaceutical companies
that responded used the glucose/galactose model to screen for
mitochondrial toxicity.
Funded by the European Innovative Medicines Initiative, the
MIP-DILI consortia has been formed to develop and evaluate
innovative mechanism-based integrated systems for the prediction
of DILI with the goal of improving the tools used to test for liver
toxicity during drug development. Within this framework we have
performed studies to deﬁne the experimental utility of the HepG2
model against a panel of selected hepatotoxicants and mitochon-
drial poisons (Table 1) using a reﬁned method with increased
mechanistic utility. Speciﬁcally, we report a method by which the
metabolic switch, glucose/galactose media change, takes place over
a 4 h period immediately prior to initiation of drug exposure rather
than adaptation over several weeks (Fig. 1), based upon work in
stem-cell derived hepatocytes and cardiomyocytes (Swiss et al.,
2013). In this way it is possible to compare the absolute effects of
metabolic modiﬁcation on drug sensitivity in cells originating from
the same source. Furthermore, most previous studies have used
long exposure to hepatotoxins with an endpoint measure of cyto-
toxicity which does not allow examination of the role of mitochon-
drial dysfunction in the absence of cell death. The biological
relevance of the screen was conﬁrmed by the measurement of
changes in mitochondrial respiration and glycolytic function using
a Seahorse analyser. Overall, these studies conﬁrm the utility of
HepG2 cells to identify certain mitochondrial toxins, although it
also highlights particular cases in which this screen is not appropri-
ate. Additionally, these studies provide a clear mechanism, by
measuring changes in cellular ATP content in the absence of cell
death, with which to evaluate the role of mitochondrial dysfunction
in the subsequent induction of cell death. However, our approach
has exempliﬁed the limitations of this assay both in terms of its
applicability to targets within the mitochondria as well as the
translatability of these in vitro screens to patients.2. Materials and methods
2.1. Materials
All Seahorse consumables were purchased from Seahorse
Biosciences (North Billerica, MA, USA), Mitochondrial ToxGlo
Assay kit and the CellTiter-Glo Assay kit were purchased from
Promega (Southampton, UK). Cytotoxicity Detection Kit was pur-
chased from Roche Diagnostics Ltd (West Sussex, UK). All forms
of Dulbecco’s modiﬁed media, Rat tail Collagen I and Phosphate
Buffered Saline (PBS) were purchased from Life Technologies
(Paisley, UK). HepG2 cells were purchased from European
Collection of Cell Cultures (ECACC, Salisbury, UK). All other reagents
and chemicals were purchased from Sigma Aldrich (Dorset, UK).2.2. Cell culture
HepG2 cells were maintained in DMEM high-glucose media
(glucose 25 mM) supplemented with fetal bovine serum
(10% v/v), L-glutamine (2 mM), sodium pyruvate (1 mM) andHEPES (1 mM). All cells were incubated under humidiﬁed air
containing 5% CO2 at 37 C. Cells were used up to passage 25.
2.3. Cell plating and metabolic switch
On the morning of the experiment WT HepG2 cells were
collected by trypsinisation and then washed three times in either
serum free glucose or galactose media (DMEM containing 25 mM
glucose or 10 mM galactose, respectively, plus supplements listed
above) before ﬁnally plating into a 96-well plate (12,000 cells/
100 ll/well). HepG2 were then incubated (4 h, 37 C, 5% CO2).
Drug stock solutions were made up in DMSO and the ﬁnal solvent
concentration was below 0.5% v/v, with a vehicle control, in each
experiment.
2.4. Assessment of mitochondrial toxicity using the Mitochondrial
ToxGlo Assay to quantify cellular ATP content alongside cell death
Following drug incubation (2 h) the Mitochondrial ToxGlo
Assay was performed according to the manufacturers’ instructions.
Brieﬂy, cytotoxicity reagent was prepared by adding bis-AAF-R110
substrate to the assay buffer (5 ll/1 ml). 20 ll of the cytotoxicity
reagent was added to each well containing 100 ll media. The plate
was shaken for one minute before incubation (37 C, 30 min). The
ﬂuorescent signal indicating dead cell protease activity was
measured at 485 nm Ex/520–530 nm Em using a plate reader
(Varioskan, Thermo Scientiﬁc). The plate then was left to equili-
brate (room temperature, 10 min). ATPase reagent (100 ll) was
added to each well, the plate was shaken (1 min) before the
luminescence signal was measured using a plate reader
(Varioskan, Thermo Scientiﬁc).
2.5. Assessment of cell viability using lactate dehydrogenase (LDH)
content of the cells with ATP assay
Cells were plated as for the Mitochondrial ToxGlo Assay. Two
plates were prepared, one plate to be used to measure the ATP
level the other for LDH dehydrogenase quantiﬁcation. Following
drug incubation (4, 8 h) ATP content was assessed using the
Promega Cell-titre glo assay according to the manufacturers’
instructions. Brieﬂy, 30 ll of ATP reagent was added to each well
containing 100 ll of media. The plate was shaken (1 min), then
100 ll of the well content was transferred to a white 96 well plate
and the ATPase luminescence was measured using a plate reader
(Varioskan, Thermo Scientiﬁc). The LDH content of the cells and
the supernatant was measured according to the manufacturer’s
instruction.
2.6. Seahorse assay
WT HepG2 cells were plated on collagen coated (50 lg/ml in
0.02 M acetic acid), XF 96-well cell culture microplates
(25,000 cells/100 ll medium/well) overnight. The culture medium
was removed from each well and replaced by 175 ll of unbuffered
Seahorse Assay media supplemented by either 25 mM glucose or
10 mM galactose, pre-warmed to 37 C. Cells were incubated in a
CO2 free incubator at 37 C for 1 h. Prior to the rate measurements,
the XFe96 Instrument (Seahorse biosciences, North Billerica, MA)
gently mixed the assay media in each well for 10 min to allow
the oxygen partial pressure to reach equilibrium. The oxygen con-
sumption rate (OCR) and extracellular acidiﬁcation rate (ECAR)
were measured simultaneously three times to establish a baseline
rate. For each measurement there was a 3 min mix followed by
3 min wait time to restore normal oxygen tension and pH in the
microenvironment surrounding the cells. Drug injection was only
performed at the end of the basal measurement cycles, to ﬁnal
Table 1
A summary of literature review for the mitochondrial liabilities of the compounds used in this manuscript.
Compound Primary use Clinical
availability
Hepatotoxic? Mitochondrial liability?
Controls Rotenone Insecticide N/Aa N/Aa Yes
CCCP Weak acid N/Aa N/Aa Yes
Antimycin-A Fish poison N/Aa N/Aa Yes
Digitonin Detergent N/Aa N/Aa No
MIP-DILI Training
compounds
Paracetamol Pain killer Available Yes mediated via
reactive metabolites
Yes (Kon et al., 2004; Parmar et al., 1995)
Amiodarone Anti-arrhythmic Black-box
warning
Yes Yes (Fromenty et al., 1990; Kennedy et al.,
1996)
Nefazodone Anxiolytic Discontinued Yes Yes (Dykens et al., 2008)
Buspirone Available Yes
Tolcapone Anti COMT Black-box
warning
Yes Yes (Korlipara et al., 2004) (Fischer et al., 2010)
Entacapone Available No
Bosentan Endothelin receptor
antagonist
Available Yes Indirectly via bile acids (Fattinger et al., 2001)
Diclofenac Nonsteroidal anti-
inﬂammatory drug
Available Yes Yes (Moreno-Sanchez et al., 1999)
Metformin Antidiabetic Available No Yes (Carvalho et al., 2008)
Perhexiline Antianginal Available Yes Yes (Kennedy et al., 1996)
Ximelagatran via active
form melagatran
Anticoagulant Withdrawn Yes No (Kenne et al., 2008)
Troglitazone Antidiabetic Withdrawn Yes Yes (Nadanaciva et al., 2007; Garcia-Ruiz et al.,
2013; Scatena et al., 2004)
Pioglitazone Available No
a Non-applicable.
Fig. 1. The work ﬂow of proposed mitochondrial toxicity screen assay (A) compared to the original strategy (B). (A) Starting with wild type HepG2 cells, cells are cultured in
serum free DMEM media containing glucose (25 mM) or galactose (10 mM) for four hours at 37 C. Cells are then exposed to the serial dilutions of the tested compound for
two hours. Cell membrane integrity and ATP level are measured for each compound in glucose or galactose media compared to the values measured in the vehicle control. (B)
The original mitochondrial toxicity model started with two different cell lines, wild type and galactose HepG2 cell lines, and then exposed the cells to the tested compound for
24 h before cell viability was measured (ATP or MTT).
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by Mitochondrial ToxGlo Assay for each compound. The duration
of the assay was 120 min.2.7. Statistical analysis
Values are expressed as a mean ± standard deviation (S.D.) cal-
culated from at least three independent experiments, denoted by n
number. Data was analysed using one way ANOVA or paired T-test
when appropriate. All calculations were performed using StatsDirect statistical software; results were considered to be signiﬁcant
when P-values were less than 0.05.3. Results and discussion
3.1. The dual assessment of cellular ATP content and cytotoxicity can
identify the early onset of mitochondrial dysfunction before cell death
in HepG2 cells
The effect of classic mitochondrial toxins with well-deﬁned
mitochondrial targets; rotenone, antimycin A and carbonyl cyanide
L. Kamalian et al. / Toxicology in Vitro 29 (2015) 732–740 735m-chlorophenyl hydrazine (CCCP) (0–100 lM), on the ATP level
and membrane integrity of HepG2 cells was examined alongside
digitonin, a non-mitochondria targeted cytotoxic detergent as a
negative control. Mitotoxicity was deﬁned by calculating the
parameters of EC50-ATP (the concentrationwhich causes a 50% drop
in ATP content) and EC150-CT (the concentration which causes a
150% increase in cytotoxicity) in glucose and galactose media from
dose–response curves (Fig. 2). In these experiments ATP levels
measured in galactose media are correlated with mitochondrial
function due to the lack of glycolytic function. After 2 h of exposure,
rotenone, CCCP and antimycin A produced an EC50-ATP in cells cul-
tured in glucose-free galactose medium at signiﬁcantly lower con-
centrations compared to those cultured in high glucose medium,
when cells remained viable. A compound is deﬁned as mitotoxic
if the difference between values for EC50-ATPglu and EC50-ATPgal,
and also the difference between EC50-ATPgal and EC150-CTgal were
statistically signiﬁcant (One Way ANOVA, p values less than 0.05)Fig. 2. The effect of rotenone, antimycin A, CCCP and digitonin exposure on ATP lev
concentrations of the compounds were used up to 100 lM in glucose or galactose serum
Key: ATP and cytotoxicity levels are reported as the percentage of the vehicle control ±
Table 2
Compounds found to be positive for mitotoxicity, alongside control compounds, following
EC50-ATP (lM) ± S.D. EC150-CTa (lM) ± S.D.
Glucose Galactose Glucose Galactose
Control compounds
Rotenone >100 0.05 ± 0.04 >100 >100
Antimycin A >100 0.003 ± 0.001 >100 49 ± 2
CCCP >100 0.90 ± 0.80 >100 >100
Digitonin 2.8 ± 1.7 2.1 ± 1.5 2.7 ± 1.5 2.7 ± 2.3
MIP-DILI training compounds
Amiodarone >300 158 ± 30 >300 196 ± 5
Nefazodone 39 ± 3 17 ± 5 76 ± 7 142 ± 59
Troglitazone 81 ± 42 28 ± 8 >300 84 ± 24
Tolcapone >300 53 ± 4 >300 >300
Buspirone >900 338 ± 105 >900 >900
The results are quoted ± standard deviation (n = 3). Key: a – cytotoxicity; P valueb indicat
the signiﬁcance of EC150-CTgal compared with EC50-ATPgal as tested by ANOVA.(Table 2). In most cases where there was calculated to be a signiﬁ-
cant difference, the EC50-ATPglu/EC50-ATPgal ratio and also the
EC150-CTgal/EC50-ATPgal were P2, which is in line with previous
publications (Swiss et al., 2013). These ratios represent different
aspects of mitochondrial toxicity. An EC50-ATPglu/EC50-ATPgal of
P2 indicates that the tested compound contains a mitochondrial
liability and thus has a more signiﬁcant effect in galactose media
due to the absence of glycolysis. An EC150-CTgal/EC50-ATPgal of
P2 is indicates that mitochondrial dysfunction precedes cell death.
3.2. The acute HepG2 metabolic model can identify drugs which induce
toxicity via mitochondrial dysfunction
3.2.1. Standard two hours exposure to limited concentrations of the
compounds
The assay was next performed using a panel of compounds,
selected by MIP-DILI as training compounds (Table 1). In theels and cytotoxicity of HepG2 cells (2 h) compared to the vehicle control. Serial
free media. The values are expressed as percentage of those of the vehicle control.
S.D. (n = 3).
2 h exposure in HepG2 cells.
EC50ATPglu/EC50ATPgal (p valueb) EC150CTagal/EC50ATPgal (p valuec)
>2000 (< 0.0001) >2000 (<0.0001)
>33,300 (<0.0001) 16,400 (0.02)
>110 (<0.0001) >110 (<0.0001)
1 (Not signiﬁcant) 1 (Not signiﬁcant)
>2 (0.001) 1 (0.001)
2 (0.047) 8 (0.016)
3 (Not signiﬁcant) 3 (0.0073)
>6 (<0.0001) >6 (<0.0001)
>3 (0.0008) >3 (0.0008)
es the signiﬁcance of EC50-ATPglu compared with EC50-ATPgal and P valuec indicates
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(Fig. 3). Four of the fourteen compounds tested; nefazodone, trogli-
tazone, amiodarone and tolcapone could be classiﬁed as containing
a mitochondrial liability (based upon the EC50-ATPglu vsFig. 3. The effect of MIP-DILI training compounds on ATP and cytotoxicity of HepG2 cells
used up to 300 lM (or 900 lM for buspirone) in glucose or galactose serum free media.
EC50-ATPglu of >2) and in which mitochondrial dysfunction precedes cell death (EC150-CT
level signiﬁcantly throughout the 2 h assay duration. (C) Compounds which were negativ
equal to 1). Key: ATP and cytotoxicity levels are reported as the percentage of the vehicEC50-ATPgal) and that mitochondrial dysfunction preceded cell
death (based upon the EC50-ATP gal vs EC150-CT gal), as deﬁned
above (Fig. 3A and Table 2). Buspirone could also be classiﬁed as
mitotoxic when an extended concentration range was used(2 h) compared to the vehicle control. Serial concentrations of the compounds were
(A) Compounds that were labelled as having a mitochondrial liability (EC50-ATPgal/
gal/EC50-ATPgal of >2). (B) Compounds which did not change the ATP or cytotoxicity
e for mitochondrial toxicity (EC50-ATPgal/EC50-ATPglu and EC150-CTgal/EC50-ATPgal
le control ± S.D. (n = 3).
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been cited as causing mitochondrial dysfunction predominantly
via some effect on the electron transport chain (Table 1).
Over 2 h seven compounds; diclofenac, bosentan, paracetamol,
metformin, pioglitazone, entacapone and ximelagatran were seen
to induce concentration-dependent increases in cellular ATP
content in both glucose and galactose medium in the absence of
cytotoxicity (Fig. 3B). This increase was most prominent for
diclofenac and bosentan (up to 140% of vehicle only). This
phenomenon has been reported previously for drugs such as vali-
nomycin (Lofrumento et al., 2011). We hypothesise that this
increase may form part of a protective mechanism and the activa-
tion of cellular defence. For example, cells may either up-regulate
ATP synthesis or switch off ATP consuming processes in order to
increase and/or maintain ATP for processes such as glutathione
synthesis or apoptotic cell death. These compounds were therefore
subject to further testing at extended concentrations; 30 mM,
10 mM, 3 mM and 1 mM for paracetamol, metformin andFig. 4. The effect of the negative MIP-DILI training compounds on ATP and cytotoxic
concentrations and time courses. The graphs show the lowest concentration and shorte
content of cells was signiﬁcantly decreased in galactose media compared to glucose me
control ± S.D. (n = 3). ⁄P < 0.05 ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 signiﬁcance as tested by ANOVA.diclofenac respectively and 2.7 mM for pioglitazone and entaca-
pone (2 h). However, this did not lead to the classiﬁcation of any
of these compounds as either positive or negative for mitochon-
drial toxicity (data not shown).
Surprisingly, the action of perhexiline, a known inhibitor of
fatty acid oxidation, closely resembled digitonin and induced cell
death in tandem with decreases in ATP levels (Fig. 3C). This ﬁnding
may result from the action of perhexiline as an inhibitor of fatty
acid oxidation via its inhibition of CPT-1, a carnitine transporter
(Kennedy et al., 1996). The compound etomoxir has been shown
to use this mechanism to induce both a decrease in OXPHOS with-
out a substantial increase in glycolysis, alongside a signiﬁcant cyto-
toxic effect due to the generation of reactive oxygen species (Pike
et al., 2011). This may explain the ﬁndings here of a decrease in
ATP occurring in both media alongside the induction of cell death.
Therefore, this assay incorrectly deﬁnes perhexilline as negative for
mitochondrial toxicity, thus exemplifying that this short assay can-
not identify all forms of mitochondrial dysfunction.ity of HepG2 cells compared to the vehicle control when exposed for extended
st time at which cells remained viable (calculated by LDH) in both media, but ATP
dia. Key: ATP and cytotoxicity levels are reported as the percentage of the vehicle
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Several of the compounds which remained unclassiﬁed in the
2 h assay are known inducers of mitochondrial dysfunction
(Table 1) and so we investigated whether this discrepancy was
due to the acute exposure by using an extended concentration
range and time course (4 or 8 h) for the remaining compounds,
except for bosentan, as it induces cholestatic injury which would
not be evident in unpolarised HepG2 cells (Fattinger et al., 2001).
Monitoring baseline cell health revealed that the method of acute
glucose starvation could only be reliably used up to 8 h and that
LDH is a more sensitive and reproducible cell death marker than
the cell death protease included in the Mitochondrial ToxGlo
Assay at these extended timepoints (data not shown). In this way
we deﬁned the shortest duration, with the lowest concentration
of drug, at which a differential effect upon ATP content was
observed in the two media in the absence of cell death (Fig. 4).
Using this classiﬁcation system, ﬁve of the seven tested com-
pounds, paracetamol, metformin, pioglitazone, diclofenac and
entacapone, could be classiﬁed as weak mitochondrial toxins in
accordance with the literature, in which each of these compounds
has been described to have a mitochondrial liability via the ETC
(Table 1). However, in the case of entacapone and pioglitazone this
liability is substantially weaker than their structurally related,
more hepatotoxic counterparts, tolcapone and troglitazone and
exempliﬁes the power of this assay in detecting the weakest
mitochondrial toxins and to rank compounds in terms of potency
of mitotoxicity. This is a clear advantage of this model system. In
each case of related compounds studied here, nefazodone and bus-
pirone; tolcapone and entacapone and troglitazone and pioglita-
zone the striking difference in potency of mitochondrial
dysfunction can be correlated with clinical hepatotoxic potential.
Speciﬁcally, entacapone, pioglitazone and buspirone are clinically
useful drugs with low rates of hepatotoxicity, in contrast to their
pairs, all of which have been withdrawn, discontinued duringFig. 5. Oxygen consumption rate (OCR) and extra cellular acidiﬁcation rate (ECAR) in Hep
HepG2 cells as a result of exposure to rotenone or CCCP at 29 min in glucose and galactos
after 29 and 120 min exposure to rotenone, CCCP, amiodarone, tolcapone, troglitazone
media, at the concentrations determined by mito-tox assay (EC50-ATPgal). Results are
⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 signiﬁcance of data treated with compound compared t
ANOVA.development or have a black-box warning for hepatotoxicity.
Moreover, although we have correctly identiﬁed the weak
mitochondrial liability within metformin it is not classiﬁed as a
clinical hepatotoxin (Table 1).
Paracetamol was unexpectedly observed to induce mitochon-
drial dysfunction after 4 h, but only at a high concentration
(30 mM). Although paracetamol is reported to target the
mitochondria, toxicity is mediated via CYP P450 mediated reactive
metabolites, especially the quinoneimine (Nelson, 1990). As it is
known that levels of many CYP enzyme isoforms are low in
HepG2 cells (Gerets et al., 2012) we carried out HPLC-MS/MS
analysis to measure the concentrations of metabolites produced
by the cells (data not shown). This revealed that the key reactive
metabolites were present only in very low levels, close to or below
the limit of detection. This correlates with iTRAQ analysis of the
HepG2 proteome (data not shown, to be published elsewhere)
which indicates the overall level of drug metabolising enzymes
in HepG2 cells to be less than approximately 1% of those found
in fresh human hepatocytes. Therefore, it is unlikely that the toxi-
city observed in these studies is related to the usual mechanism of
paracetamol toxicity via the formation of reactive metabolites.
Ximelagatran was negative as a mitotoxin throughout these
experiments which was anticipated (Kenne et al., 2008).
However, Ximelagatran is a pro-drug; the active component,
melagatran, is formed via two intermediate metabolites (hydroxyl
melagatran and ethyl-melagatran) with formation mediated via
non-CYP P450 enzyme systems (Clement and Lopian, 2003;
Eriksson et al., 2003). Therefore it was considered important to
determine whether the active metabolite was produced in the
model systems utilised here. HPLC-MS/MS analysis detected
insigniﬁcant levels of melagatran and the two intermediate
metabolites (data not shown) and hence it is not possible to
unequivocally rule out mitochondrial toxicity induced by metabo-
lism of Ximelagatran using this assay.G2 cells in response to drug exposure. (A) and (B) Shift in the bioenergetic proﬁle of
e media. (C) and (D) Percent fold change of OCR and ECAR to the basal measurement
, buspirone, nefazodone, ximelagatran and vehicle control (0.5% DMSO) in glucose
reported as the percentage fold change compared to the basal level ± S.D. (n = 3).
o basal respiration (A and B) or compared to vehicle control (C and D), as tested by
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the compounds upon cellular respiration
In order to conﬁrm that the ATP measurements are representa-
tive of the functional effects on the mitochondria Seahorse
technology was used to deﬁne the bioenergetic phenotype of the
cells cultured with and in the absence of glucose and to determine
how this affects their response to mitochondrial toxicants. Cells in
both conditions had similar basal phenotypes in terms of OCR
(indicative of OXPHOS rates) and ECAR (indicative of glycolysis
rates) with differences only becoming apparent once cells were
exposed to mitochondrial toxins (Fig. 5). Although rotenone
induced a similar decrease in OCR in both media at 29 min, only
in glucose media is this accompanied by a signiﬁcant increase in
ECAR (Fig. 5A). In response to CCCP, OCR was only signiﬁcantly
increased in galactose whilst ECAR was only signiﬁcantly increased
in glucose media (Fig. 5B). In each case the signiﬁcant increase in
ECAR is only measured when cells are cultured in the presence of
glucose as this allows the compensatory increase in glycolysis thus
demonstrating the metabolic mechanisms underlying the acute
glucose deprivation screen for mitochondrial damage.
Using this protocol to measure respiration in glucose media tro-
glitazone, nefazodone, buspirone and amiodarone were seen to
behave in a fashion similar to rotenone; decreasing OCRwith a con-
comitant increase in ECAR (Fig. 5C and D), indicative of their ability
to induce mitochondrial dysfunction via inhibition of the electron
transport chain (Table 1). The compounds generated similar results
in galactose media (data not shown). Interestingly, amiodarone and
tolcapone did not increase OCR, as would be expected, due to their
reported action as uncouplers of respiration. Further work revealed
that this discrepancy was not concentration related (data not
shown). However, amiodarone has been described to have
pleiotropic effects on the mitochondria; it is an uncoupler and also
an inhibitor of the electron transport chain and b-oxidation, and
this may underlie this result (Fromenty et al., 1990; Kennedy
et al., 1996). Moreover, tolcapone has been identiﬁed as an uncou-
pler and inhibitor of several complexes of the electron transport
chain (Table 1). These results suggest that bioenergetic proﬁle pat-
terns are compound dependent and that the mitotoxicity screen
may be more sensitive at deﬁning mitotoxicity via ETC dysfunction
than screening basal OCR and ECAR. However, Seahorse technology
may be important when conducting further in-depth mechanistic
investigations of the cause of mitotoxicity.4. Conclusion
HepG2 cells are used extensively as a preclinical model during
pharmaceutical drug discovery and development despite their lack
of xenobiotic metabolic capacity, altered bioenergetic phenotype
and lack of polarisation. Therefore, it is often postulated that
HepG2 cells are of limited relevance to clinical hepatotoxicity.
However, in terms of detecting mitochondrial toxicity we postulate
that the tumorigenic bioenergetic phenotype of HepG2 cells is an
advantage over fresh human hepatocytes (FHH). Speciﬁcally, the
Warburg effect, which confers tumorigenic cells with the ability
to utilise glycolysis as an additional mechanism to produce ATP
when needed, does not occur in primary hepatocytes (Warburg,
1956). Therefore, although FHH are able to detect cell toxicity/
death caused via mitochondrial dysfunction, their ﬁxed bioener-
getic phenotype means that they lack the advantage of HepG2 cells
in determining mechanistically whether cytotoxicity arises due to
mitochondrial dysfunction as the glucose/galactose switch cannot
be applied.
Overall, we have demonstrated that HepG2 cells acutely
deprived of glucose are a suitable model for the identiﬁcation ofmitochondrial toxicity when used alongside HepG2 cells in the
presence of glucose. Furthermore, the dual assessment of ATP con-
tent alongside cytotoxicity provides an enhanced mechanistic
understanding of the causes of toxicity. Importantly, in this way
ATP is a functional endpoint indicative of mitochondrial respiration
which is sensitive enough to be measured early in toxicity, in the
absence of cell death. This has allowed the identiﬁcation of the
time-dose window of the onset of mitochondrial dysfunction
enabling the delineation of ensuing changes in cellular function
to be assessed in a cause and effect manner. The utility of this assay
to identify compounds which induce dysfunction of the ETC
directly has been proven, with zero to low levels of false positive
results. However, the use of a panel of hepatotoxins has also high-
lighted limitations of the screen in detecting alternative mecha-
nisms of mitochondrial dysfunction or mitotoxicity induced via
reactive metabolites or fatty acid oxidation. The functional model
developed here is able to give information on the potency of a ser-
ies of compounds upon mitochondrial dysfunction which may be
indicative of the propensity to cause hepatotoxicity. However, it
cannot be used to replace the current preclinical testing strategies
to predict compounds which will induce hepatotoxicity, as there is
no clear link between the concentrations which cause mitochon-
drial dysfunction and peak plasma concentration in humans.
Therefore we propose that this updated method provides a sensi-
tive, convenient, cost effective and fast ﬁrst tier screening platform
to identify mitochondrial liabilities during drug development
which should be used for parent compound alongside synthetic
equivalents of any signiﬁcant human drug metabolites. However,
we emphasise that despite the very low false positive rate of this
method, the compounds identiﬁed as negative by this model
should go through further cytotoxicity assessment in order to rule
out their cyto- or hepato-toxicity. This method therefore provides a
starting point from which to conduct further studies delineating
the mechanistic pathways linking mitochondrial toxicity with the
onset of DILI.
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